Selected article for: "active site and inhibitor treatment"
Author: Drayman, Nir; Jones, Krysten A.; Azizi, Saara-Anne; Froggatt, Heather M.; Tan, Kemin; Maltseva, Natalia Ivanovna; Chen, Siquan; Nicolaescu, Vlad; Dvorkin, Steve; Furlong, Kevin; Kathayat, Rahul S.; Firpo, Mason R.; Mastrodomenico, Vincent; Bruce, Emily A.; Schmidt, Madaline M.; Jedrzejczak, Robert; Muñoz-Alía, Miguel Á.; Schuster, Brooke; Nair, Vishnu; Botten, Jason W.; Brooke, Christopher B.; Baker, Susan C.; Mounce, Bryan C.; Heaton, Nicholas S.; Dickinson, Bryan C.; Jaochimiak, Andrzej; Randall, Glenn; Tay, Savaş
Title: Drug repurposing screen identifies masitinib as a 3CLpro inhibitor that blocks replication of SARS-CoV-2 in vitro
  • Cord-id: x6hc4bhn
  • Document date: 2020_9_1
    • ID: x6hc4bhn
    Snippet: There is an urgent need for anti-viral agents that treat SARS-CoV-2 infection. The shortest path to clinical use is repurposing of drugs that have an established safety profile in humans. Here, we first screened a library of 1,900 clinically safe drugs for inhibiting replication of OC43, a human beta-coronavirus that causes the common-cold and is a relative of SARS-CoV-2, and identified 108 effective drugs. We further evaluated the top 26 hits and determined their ability to inhibit SARS-CoV-2,
    Document: There is an urgent need for anti-viral agents that treat SARS-CoV-2 infection. The shortest path to clinical use is repurposing of drugs that have an established safety profile in humans. Here, we first screened a library of 1,900 clinically safe drugs for inhibiting replication of OC43, a human beta-coronavirus that causes the common-cold and is a relative of SARS-CoV-2, and identified 108 effective drugs. We further evaluated the top 26 hits and determined their ability to inhibit SARS-CoV-2, as well as other pathogenic RNA viruses. 20 of the 26 drugs significantly inhibited SARS-CoV-2 replication in human lung cells (A549 epithelial cell line), with EC50 values ranging from 0.1 to 8 micromolar. We investigated the mechanism of action for these and found that masitinib, a drug originally developed as a tyrosine-kinase inhibitor for cancer treatment, strongly inhibited the activity of the SARS-CoV-2 main protease 3CLpro. X-ray crystallography revealed that masitinib directly binds to the active site of 3CLpro, thereby blocking its enzymatic activity. Mastinib also inhibited the related viral protease of picornaviruses and blocked picornaviruses replication. Thus, our results show that masitinib has broad anti-viral activity against two distinct beta-coronaviruses and multiple picornaviruses that cause human disease and is a strong candidate for clinical trials to treat SARS-CoV-2 infection.

    Search related documents:
    Co phrase search for related documents
    • accession number and active site: 1
    • action mechanism and acute respiratory distress syndrome: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24
    • action mechanism and acute respiratory distress syndrome ards: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17
    • action mechanism and additional antiviral: 1, 2, 3
    • action mechanism and luciferase activity: 1
    • active group and acute respiratory distress syndrome: 1, 2
    • active group and acute respiratory distress syndrome ards: 1, 2
    • active group and luciferase activity: 1
    • active site and acute respiratory distress syndrome: 1, 2
    • active site and acute respiratory distress syndrome ards: 1, 2
    • active site and additional antiviral: 1
    • active site and low resolution: 1, 2
    • active site and luciferase activity: 1
    • acute respiratory distress syndrome and local delivery: 1, 2
    • acute respiratory distress syndrome and luciferase activity: 1, 2, 3
    • acute respiratory distress syndrome ards and local delivery: 1
    • acute respiratory distress syndrome ards and luciferase activity: 1, 2